INTERIM REPORT
1 JANUARY – 31 MARCH 2023

Strong organic growth

SEK
2457
m

NET SALES

SEK
366
m

EBITA

-17
%

EARNINGS GROWTH
EBITA R12 MONTHS

55
%

P/WC

Fredrik Dalborg Q3 2022

Strong organic growth in both business areas

AddLife started 2023 with a strong first quarter. Healthcare activity levels are clearly recovering in all markets and the number of elective surgical procedures is increasing.

In 2021 and 2022, the company positioned itself to meet the demand that the increased number of elective surgical procedures was expected to drive once the effects of the pandemic subsided. We are now seeing this development materialise, which in the quarter resulted in strong organic growth of 12 percent.

A leading player in Life Science

AddLife is a listed Swedish Medtech company active on the European market. AddLife owns and acquires companies in niche segments with offerings aimed primarily at the healthcare sector, from research to medical care. The subsidiaries are divided into two business areas. Labtech offers products, solutions and a wide range of diagnostic services, biomedical research and laboratory analysis. Medtech offers products, solutions and services in medical technology and home care.